ResMed
771 hedge funds and large institutions have $16.4B invested in ResMed in 2024 Q2 according to their latest regulatory filings, with 117 funds opening new positions, 307 increasing their positions, 241 reducing their positions, and 55 closing their positions.
113% more first-time investments, than exits
New positions opened: 117 | Existing positions closed: 55
27% more repeat investments, than reductions
Existing positions increased: 307 | Existing positions reduced: 241
7% more funds holding
Funds holding: 718 → 771 (+53)
1.78% more ownership
Funds ownership: 56.7% → 58.48% (+1.8%)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
0% less capital invested
Capital invested by funds: $16.5B → $16.4B (-$51.9M)
34% less call options, than puts
Call options by funds: $180M | Put options by funds: $272M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
+$398M |
| 2 |
Morgan Stanley
New York
|
+$296M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$81.9M |
| 4 |
Millennium Management
New York
|
+$78.9M |
| 5 |
GC
Greenvale Capital
London,
United Kingdom
|
+$55.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
-$222M |
| 2 |
JP Morgan Chase
New York
|
-$144M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$121M |
| 4 |
BlackRock
New York
|
-$102M |
| 5 |
ATO
Alecta Tjanstepension Omsesidigt
Stockholm,
Sweden
|
-$98M |
RMD Hedge Fund Activity: Q2 2024 in Review
771 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in ResMed (RMD) for Q2 2024, worth a combined $16.4B — down 0.31% from $16.5B a quarter earlier.
Buyers outnumbered sellers: 117 funds opened new RMD positions and 55 closed out — a net gain of 62 holders — while 307 added to existing stakes and 241 trimmed.
The largest buyer was Bank of New York Mellon, adding an estimated $398M. The largest seller was Norges Bank, cutting an estimated $222M.
- 771 institutional investors held ResMed (RMD) as of Q2 2024, up from 718 in Q1 2024.
- Funds reported $16.4B of ResMed stock for Q2 2024, down 0.31% quarter-over-quarter.
- 117 funds opened new ResMed positions in Q2 2024 and 55 closed out, a net change of +62 holders.
- The largest ResMed buyer in Q2 2024 was Bank of New York Mellon, an estimated $398M added.
- The largest ResMed seller in Q2 2024 was Norges Bank, an estimated $222M sold.
Based on aggregated 13F filings for Q2 2024.